X-TROZINE Drug Patent Profile

When do X-trozine patents expire, and when can generic versions of X-trozine launch?

X-trozine is a drug marketed by Shire Richwood and is included in seven NDAs.

The generic ingredient in X-TROZINE is phendimetrazine tartrate. There are five drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the phendimetrazine tartrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for X-trozine

A generic version of X-TROZINE was approved as phendimetrazine tartrate by CHARTWELL on October 30^th, 1991.

Summary for X-TROZINE

US Patents:	0
Applicants:	1
NDAs:	7
Raw Ingredient (Bulk) Api Vendors:	20
DailyMed Link:	X-TROZINE at DailyMed

US Patents and Regulatory Information for X-TROZINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Shire Richwood	X-TROZINE	phendimetrazine tartrate	CAPSULE;ORAL	087394-001	Sep 22, 1982		DISCN	No	No
Shire Richwood	X-TROZINE L.A.	phendimetrazine tartrate	CAPSULE, EXTENDED RELEASE;ORAL	087371-001	Aug 24, 1982		DISCN	No	No
Shire Richwood	X-TROZINE	phendimetrazine tartrate	TABLET;ORAL	086552-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Shire Richwood	X-TROZINE	phendimetrazine tartrate	TABLET;ORAL	086550-001	Approved Prior to Jan 1, 1982		DISCN	No	No

X-TROZINE Market Analysis and Financial Projection

Last updated: April 24, 2026

X-TROZINE: Market Dynamics and Financial Trajectory

No market, financial, or patent-relevant information is available in the provided context to produce a complete, accurate market-dynamics and financial-trajectory analysis for “X-TROZINE.”

What is the commercial footprint of X-TROZINE?

Insufficient information to determine:

• Launch geography and timeline
• Current approved indications and label scope
• Pricing, reimbursement status, or distribution channels
• Present market share by geography or segment

How is X-TROZINE selling (revenue path and growth drivers)?

Insufficient information to determine:

• Any reported sales (unit or revenue) over time
• Forecasted revenue trajectory
• Key growth or decline drivers (new indications, line extensions, formulary changes)

What competitive forces shape X-TROZINE pricing and volume?

Insufficient information to determine:

• Competitor set (direct and indirect)
• Competitive efficacy/safety positioning
• Patent or exclusivity status of incumbents and peers
• Evidence of tender dynamics, contracting behavior, or class-wide drug substitution

What is the financial trajectory investors would model (unit economics and cash burn)?

Insufficient information to determine:

• Company-level financials tied to X-TROZINE (R&D, commercialization spend)
• Gross margin drivers (manufacturing cost, royalties, platform economics)
• Milestone or royalty streams associated with commercialization
• Discount rates used in underwriting scenarios

What patent and regulatory constraints impact long-term value?

Insufficient information to determine:

• Patent estate coverage (composition, method, process, formulations)
• Country-by-country expiry and exclusivity periods
• Regulatory milestones (PDUFA timelines, line-of-therapy barriers)
• Potential generic or biosimilar entry risks

Key Takeaways

• X-TROZINE market dynamics and financial trajectory cannot be determined from the provided information.
• No actionable conclusions on sales trajectory, pricing pressure, competitive position, or patent-driven value can be produced.

FAQs

1. What is X-TROZINE’s current revenue trajectory?
   Cannot be determined from the provided context.

2. Which countries are driving X-TROZINE sales?
   Cannot be determined from the provided context.

3. Who are X-TROZINE’s main competitors and how do they impact pricing?
   Cannot be determined from the provided context.

4. What patent expiry and exclusivity milestones govern X-TROZINE’s long-term value?
   Cannot be determined from the provided context.

5. What commercialization spend and margins should be used to model cash flows?
   Cannot be determined from the provided context.

References

[1] No sources were provided in the prompt.